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respectively) (Figure 2b and c). Other
factors were not correlated with serum
CTACK/CCL27 levels (data not shown).
In this study, we showed that serum
CTACK/CCL27 levels in patients with
CTCL strongly correlated with types of
skin lesions, TBI, serum soluble IL-2
receptor, and thymus and activation-
regulated chemokine/CCL17 levels, all
of which are already reported to be
good makers of disease activity (Wasik
et al., 1996; Schmid et al., 1999;
Kakinuma et al., 2003b). In addition,
serum CTACK/CCL27 levels in patients
with CTCL decreased after treatment.
This is the first report describing the
relationship between CTACK/CCL27
and CTCL. CTACK/CCL27 is expressed
at a small amount even in normal skin
(Kakinuma et al., 2003a) and that may
be the reason of a large overlap of
CTACK/CCL27 levels between healthy
controls and an early stage of CTCL
(Figure 1a). Serum CTACK/CCL27 le-
vels in patients with tumor were higher
than those in erythrodermic patients
probably because three out of five
patients with skin tumor had systemic
involvement. In addition, erythroder-
mic CTCL is very rare and the number
of cases may not be enough. Therefore,
further study with larger number of
patients would be useful to fully deter-
mine the potential usefulness of
CTACK/CCL27 levels as a treatment-
and diagnosis-related biomarker.
Previous reports showed that CCR10
is expressed in CTCL (Notohamiprodjo
et al., 2005) and that CCR10 engage-
ment by CTACK/CCL27 allows mela-
noma cells to escape host immune anti-
tumor killing mechanisms (Murakami
et al., 2003). The same pathway may be
involved when CTCL cells escape host
immunity. Our data suggest its possibi-
lity and that functional blocking of
CTACK/CCL27 would be another target
for treatment.
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TO THE EDITOR
The number of human diseases in
which the immunomodulatory effects
of UV radiation play a role is expand-
ing, and include not only the develop-
ment of skin cancers but also
autoimmune and infectious diseases.
In addition, UV has long been recog-
nized as an important therapeutic for
the treatment of inflammatory skin
conditions. Molecules in skin that
absorb UV radiation include the DNA
and membrane lipids of epidermal
cells, as well as trans-urocanic acid
(trans-UCA), a major molecule of the
stratum corneum. On irradiation, it is
converted to the more soluble cis-
isomer. The action spectrum of UVB-
induced systemic suppression of con-
tact hypersensitivity responses in mice
closely follows the absorption spectrum
of UCA (De Fabo and Noonan, 1983).
Abbreviations: DOI, 2,5-dimethoxy-4-iodophenyl-2-aminopropane; 5-HT, 5-hydroxytryptamine;
LPS, lipopolysaccharide; PBMC, peripheral blood mononuclear cell; PGE2, prostaglandin E2;
TNF-a, tumor necrosis factor-alpha; UCA, urocanic acid
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The role of cis-UCA in UV-induced
immunomodulation varies with the
response examined and the experimen-
tal model adopted, but significant roles
have been confirmed by neutralization
studies with a cis-UCA monoclonal
antibody (reviewed in Ullrich, 2005).
In vitro effects of cis-UCA have been
described on purified keratinocytes,
Langerhans cells, fibroblasts, T lympho-
cytes, natural killer cells, monocytes,
and recently on peripheral sensory
nerves (reviewed in Khalil et al.,
2001). The receptor for cis-UCA, a
potential target for therapeutic interven-
tion, has however not been identified.
Further, characterization of the receptor
for cis-UCA may provide insights into
the biological actions of cis-UCA.
At first, it was hypothesized that cis-
UCA bound to histamine receptors, but
the different biological effects of hista-
mine and cis-UCA (Hart et al., 1993;
Bouscarel et al., 1997) as well as poor
competitive binding to rat cortex mem-
branes (Laihia et al., 1998) showed that
cis-UCA did not bind to histamine
receptors. Instead, 103 M cis-UCA,
but not trans-UCA, was able to com-
pete off to approximately 50% the
binding of radiolabeled g-amino-buty-
ric acid to rat cortical membranes
(Laihia et al., 1998). The finding
that cis-UCA, but not g-amino-butyric
acid, alters microvascular blood flow at
the base of a blister induced in the rat
hind footpad (Khalil et al., 2001)
suggests that the functional cis-UCA
receptor is not the g-amino-butyric acid
receptor.
More recently, it has been recog-
nized that cis-UCA and serotonin share
structural similarities. Cis-urocanic acid
has a 5-membered ring with the inner
nitrogen sharing a strong intramolecular
hydrogen bond with the carboxylic acid
moiety. In aqueous solution, this forms
a stable six membered ring similar in
structure to that of serotonin (Ash et al.,
1997). Further, it has been suggested
that both cis-UCA and serotonin bind to
the 5-hydroxytryptamine (5-HT)2A re-
ceptor (Ngheim DX, Walterscheid JP,
Nutt LK, McConkey DJ, Ullrich SE
(2002) Cis-urocanic acid causes immu-
nosuppression through 5-HT receptor
signaling. Proc Mutag Exp Path Soc
Aust (abstr. 14)), to which the agonist,
2,5-dimethoxy-4-iodophenyl-2-amino-
propane (DOI) also binds (Johnson
et al., 1987).
To further analyze the receptor for
cis-UCA and in experiments approved
by the Princess Margaret Hospital
Ethics Committee, human peripheral
blood mononuclear cells (PBMC) were
incubated with lipopolysaccharide
(LPS) and regulation of tumor necrosis
factor-alpha (TNFa) and prostaglandin
E2 (PGE2) production examined.
Cis-UCA (Hart et al., 1993), serotonin,
and DOI (Cloez-Tayarani et al., 2003)
can suppress TNF-a production by
human PBMCs. However, in the
absence of any cell death, the mechan-
ism by which TNF-a production was
suppressed varied and suggested use
of different membrane receptors by
cis-UCA, serotonin, and the 5-HT2A
receptor agonist. Suppression of LPS-
induced TNF-a production by cis-UCA
(X7106 M) was completely reversed
by incubation with indomethacin
(105 M) (Figure 1a). However, signifi-
cant suppression by serotonin and
DOI of LPS-induced TNF-a production
was consistently detected in the
presence of indomethacin (Figure 1b
and c). Measurement of PGE2 levels in
the culture supernatants supported
these results. Cis-UCA induced PGE2
production in a dose-dependent man-
ner (Figure 2a), whereas there was a
consistent increase in response to ser-
otonin only at the very highest (supra-
physiological) concentration of 103 M
(Figure 2b). DOI had no significant
effect on LPS-induced PGE2 production
(Figure 2c). In a further experiment, we
hypothesized that if serotonin and
cis-UCA competitively bound to the
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Figure 1. The effect of indomethacin (105 M) on the regulation of LPS-
induced TNF-a production by (a) cis-UCA, (b) serotonin, and (c) DOI.
PBMCs from three separate donors were incubated with LPS (500 ng/ml) for
24 h,7 the potential regulators. LPS-induced level has been normalized to
100%, mean7SEM, with * and # showing significant suppression
compared with LPS-treated cells without and with Indo, respectively,













































































Figure 2. The effect of (a) cis-UCA, (b) serotonin, and (c) DOI on LPS-
induced PGE2 production. PGE2 was measured in the same supernatants
for which TNF-a levels are shown in Figure 1 (no PGE2 was detected in
indomethacin-treated cultures). In (d), PBMCs from two further donors
were incubated with cis-UCA, together with a concentration of serotonin
(104 M) that did not significantly induce PGE2 levels. Mean7SEM;
*significant induction compared with LPS-treated controls, Po0.05.
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should affect PGE2 production in re-
sponse to cis-UCA. This did not happen
(Figure 2d).
Cis-UCA and serotonin did not have
the same biological effects on PBMCs, a
result confirmed using monocytes ob-
tained by elutriation (485% enriched).
Further, the biological effects of DOI,
an agonist of the 5HT2A receptor, on
TNF-a and PGE2 production by LPS-
stimulated cells suggested that cis-UCA
was not binding to this receptor. Studies
with agonists of the 5-HT3, 5-HT4, and
5-HT7 receptors also did not have the
same functional outcomes as cis-UCA
(data not shown). Further, serotonin
(Cloez-Tayarani et al., 2003; Durk
et al., 2005) but not cis-UCA (Hart
et al., 1993) can induce IL-1b produc-
tion by LPS-stimulated monocytes.
We conclude that the effects of
cis-UCA on PBMCs are not mediated
via the receptor to which serotonin
binds. These findings suggest that
cis-UCA, and serotonin if it is
involved, signal independently in
pathways of UVB-induced immunomo-
dulation.
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